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ab T-cell receptors from multiple sclerosis
brain lesions show MAIT cell–related
features
ABSTRACT
Objectives: To characterize phenotypes of T cells that accumulated in multiple sclerosis (MS)
lesions, to compare the lesional T-cell receptor (TCR) repertoire of T-cell subsets to peripheral
blood, and to identify paired a and b chains from single CD81 T cells from an index patient who
we followed for 18 years.
Methods: We combined immunohistochemistry, laser microdissection, and single-cell multiplex
PCR to characterize T-cell subtypes and identify paired TCRa and TCRb chains from individual
brain-infiltrating T cells in frozen brain sections. The lesional and peripheral TCR repertoires were
analyzed by pyrosequencing.
Results: We found that a TCR Vb11 T-cell population that was strikingly expanded in active brain
lesions at clinical onset comprises several subclones expressing distinct yet closely related
Va7.21 a chains, including a canonical Va7.2-Ja33 chain of mucosal-associated invariant T
(MAIT) cells. Three other a chains bear striking similarities in their antigen-recognizing, hyper-
variable complementarity determining region 3. Longitudinal repertoire studies revealed that the
TCR chains that were massively expanded in brain at onset persisted for several years in blood or
CSF but subsequently disappeared except for the canonical Va7.21 MAIT cell and a few other
TCR sequences that were still detectable in blood after 18 years.
Conclusions: Our observation that a massively expanded TCR Vb1-Jb2.3 chain paired with dis-
tinct yet closely related canonical or atypical MAIT cell–related a chains strongly points to an
antigen-driven process in early active MS brain lesions. Neurol Neuroimmunol Neuroinflamm
2015;2:e107; doi: 10.1212/NXI.0000000000000107
GLOSSARY
CDR 5 complementarity determining region; FITC 5 fluorescein isothiocyanate; MAIT 5 mucosal-associated invariant T;
MR1 5 MHC-related molecule 1; MS 5 multiple sclerosis; PBMC 5 peripheral blood mononuclear cell; PBS 5 phosphate-
buffered saline; TCR 5 T-cell receptor.
CNS-invasive, presumably autoreactive T cells are believed to play a central role in the patho-
genesis of multiple sclerosis (MS).1–3 In parenchymal MS brain infiltrates, CD81 T cells are
more frequent than CD41 T cells.4–7 Furthermore, CNS-infiltrating CD81 T cells are oligo-
clonal,6–10 whereas CD41 T-cell infiltrates tend to be more polyclonal.6 Some CD81 T-cell
clones were shown to be expanded not only in the brain but also in CSF and blood, where they
may persist for years.6
For technical reasons, most previous studies of the T-cell receptor (TCR) repertoire were lim-
ited to the b chain. However, the antigen-specific TCR is an ab heterodimer, and both chains
contribute to antigen recognition. Here we used immunohistochemistry, laser microdissection,
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and single-cell multiplex PCR11 to identify
paired ab TCRs from brain-infiltrating
CD81 T cells present in an early active lesion
from “patient A,”6 whom we have followed for
18 years. We found that a clonally expanded
and persisting Vb1-Jb2.3 chain pairs with sev-
eral distinct yet closely related Va7.21 a
chains. It is intriguing that one of the newly
identified TCR a chains is characteristic for
mucosal-associated invariant T (MAIT) cells,
and 3 other a chains are highly homologous.
MAIT cells are an innate-like T-cell subset
with limited TCR variability12 that express
the TCR Va7.2 element and the natural killer
cell marker CD16113–16 and are restricted by
the MHC-related molecule 1 (MR1).17 MAIT
cells are a heterogeneous, semi-invariant T-cell
population, with most cells carrying a “canon-
ical” TCR a chain defined by the usage of
Va7.2 and Ja33 and some cells carrying a
“noncanonical” TCR a chain in which Ja33
is replaced by Ja12 or Ja20.15 Their develop-
ment depends on gut microbiota, and they are
thought to play a role in defense against vari-
ous microorganisms.17–19 Because we found
not only canonical MAIT a chains but also
different, though homologous, a chains pair-
ing with one b chain, our results illustrate the
complexity of the CD81 T-cell repertoire.
METHODS Standard protocol approvals, registrations,
and patient consents. Written consent from patient A was ob-
tained according to the Declaration of Helsinki. The study was
approved by the ethics committee of the medical faculty of the
LMU Munich.
Patient A. The male patient A initially presented with left-sided
hemianopia in 1996. His initial cranial MRI showed a large right
temporo-occipital white matter lesion, raising suspicion of
malignant glioma.5 Two weeks after onset of his clinical
symptoms, the brain lesion was neurosurgically resected.
Histopathology showed an inflammatory demyelinating lesion
consistent with MS. Subsequently he had a typical relapsing-
remitting course of MS. He has been continuously treated with
interferon-b-1a IM from the time of his third relapse in 1998 until
submission of this manuscript. Figure e-1 at Neurology.org/nn
gives an overview of the course of experiments. Blood samples for
this study were taken in 2003, 2005, 2013, and 2014. Written
consent was obtained from the donor.
Immunohistochemistry. The resected brain tissue was imme-
diately frozen in liquid nitrogen and stored at 280°C until fur-
ther use. Frozen sections of 10 mm were cut, mounted on
positively charged slides (Superfrost Plus, Menzel, Braunschweig,
Germany) for immunohistochemistry or on membrane-covered
PET slides (Zeiss, Jena, Germany) for laser capture microscopy,
and directly stored at 220°C or 280°C, respectively.
Immunohistochemistry and microdissection was applied to
tissue regions that contain lesions with high numbers of CD81
T cells.
To characterize T-cell infiltrates in sections of MS brain, the
following antibodies against cell surface molecules were used:
mouse anti-human CD161 (1:5, 191B8, Miltenyi Biotec,
Bergisch Gladbach, Germany), mouse anti-human Va7.2 (1:5,
3C10, BioLegend, San Diego, CA), mouse anti-human CD8a
(1:50, LT8, AbD Serotec, Kidlington, UK; labeled with the Cy3
MAb labeling kit, GE Healthcare, Freiburg, Germany), rabbit
anti-human CCR7 (1:800, Y59, Abcam, Cambridge, UK),
mouse anti-human CD45RA (1:250, HI100, BioLegend), mouse
anti-human CD45RO (1:250, UCHL1, BioLegend), fluorescein
isothiocyanate (FITC)-labeled mouse anti-human Vb1 (1:100,
BL37.2, Beckman Coulter, Brea, CA), rabbit anti-human
CD3 (1:500, Dako, Glostrup, Denmark), and Alexa Fluor
488–conjugated mouse anti-human CD4 (1:50, RPA-T4, eBio-
science, San Diego, CA). Frozen sections of CNS were thawed at
room temperature, fixed in acetone, rehydrated in phosphate-
buffered saline (PBS), and blocked with 2% bovine serum albu-
min in PBS. For staining with anti-Va7.2 and anti-CD161 anti-
bodies, samples were fixed in 4% paraformaldehyde for
10 minutes. Sections were then incubated for 1 hour with the
primary antibodies at room temperature and subsequently—in
cases where the primary antibody was not directly conjugated to a
detectable fluorophore—the bound primary antibody was de-
tected using a secondary Alexa Fluor 488–labeled goat anti-
mouse IgG antibody (1:1,000, Life Technologies, Carlsbad,
CA). For double staining of Va7.2 and CD161, an Alexa Fluor
568–labeled goat anti-mouse IgG1 or an Alexa Fluor 488–labeled
goat anti-mouse IgG2a antibody (1:1,000, Life Technologies)
was used, respectively. If a FITC-labeled primary antibody was
used, the signal was enhanced using an anti-FITC Alexa Fluor
488–conjugated secondary antibody (1:100, Life Technologies).
For dual stainings with anti-CD8a, the Cy3-labeled anti-CD8a
antibody was applied last. Slides were mounted using fluorescent
mounting medium (Dako). Staining was visualized using an
Olympus FV 1000 confocal microscope with a 403 water 1.15
NA objective or a Zeiss Axioplan 2 microscope.
Isolation of T cells from peripheral blood mononuclear
cells. Peripheral blood mononuclear cells (PBMCs) were isolated
from ethylenediaminetetraacetic acid blood in 2003 by standard-
density centrifugation using Percoll (Pan-Biotech, Aidenbach,
Germany) and double stained with mouse anti-human Vb1
(clone BL37.2) and CD81 (clone LT8). CD81Vb11 double-
positive T cells were sorted using a BD FACSVantage SE flow
cytometer and analyzed by single-cell PCR. Cells were either
sorted directly into PCR tubes or obtained as bulk and then
isolated by hand under a microscope. CD81 T cells from 2003
to 2005 were analyzed by complementarity determining region
(CDR) 3 spectratyping, as described previously.6
To isolate MAIT cells from PBMCs in 2013 and 2014, T cells
were negatively isolated using the pan T-cell isolation kit (Miltenyi
Biotec) and subsequently stained with the FITC-labeled mouse anti-
human Va7.2 (1:20, 3C10, BioLegend) and the allophycocyanin-
labeled mouse anti-human CD161 (1:10, 191B8, Miltenyi Biotec)
antibodies at 4°C for 30 minutes. Cells were then sorted using a BD
FACSAriaTM2 flow cytometer. 53 102 CD1611Va7.21 cells, 63
103 CD1612Va7.21 cells, 1 3 105 CD1611 cells, and 2 3 105
CD1612 cells were collected. CD41 and CD81 T cells were posi-
tively isolated from PBMCs in 2013 and 2014 using magnetic beads
(Miltenyi Biotec).
Laser microdissection and single-cell PCR. Single Vb11CD8a1
T cells were isolated by microdissection as described,7 with the
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exception that we replaced the anti-Vb5 antibody with the anti-
Vb1 antibody BL37.2. TCRs of single Vb11CD8a1 cells ob-
tained by microdissection or by flow cytometry were analyzed by
reverse transcription PCR as described.11 PCR products were sep-
arated using a 2% agarose gel, and promising bands were excised
and submitted to sequencing after isolation of DNA by the MinE-
lute Gel Extraction Kit (Qiagen, Hilden, Germany). Throughout
this manuscript, the nomenclature according to Arden et al.20 is
used for the TCR V region.
Next-generation sequencing. For the analysis of the Va7.2
chains, RNA was isolated from sorted cells using Trizol (Life
Technologies), and complementary DNA was transcribed using
the Qiagen One Step RT-PCR Kit (Qiagen). Two rounds of
nested PCR were performed using the primers TRAV1-2-for-
out, Ca-rev-out, TRAV1-2-for-in, and Ca-rev-in.11 The inner
primers were extended for tags CS1 and CS2, barcodes MIDXX,
and 454Ti-A and 454Ti-B adaptors according to the Access Array
System 454 user guide (Fluidigm, San Francisco, CA). Samples
were pooled in equimolar concentrations.
The library for sequencing all TCR b chains was prepared
using 59-RACE (Clontech, Mountain View, CA), with the gene-
specific primers in the constant region CbRT11 (20 mM) and the
59 adaptor (10 mM; 59-AAGCAGTGGTATCAACGCAGAG-
TACTCTT(rG)539). This was followed by 2 nested PCRs for
20 cycles, each for 20 seconds at 94°C, 20 seconds at 60°C, and
50 seconds at 72°C using gene-specific reverse primers Cb-mid
and Cb-in.21 Cb-in was extended for barcodes and the adaptor
454Ti-B. As forward primers we used the step-out primers sa1:
CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAA-
CGCAG; sa2: 454TiA_MIDXX_CTAATACGACTCACTA-
TAGGGC. PCR products were excised from agarose gels,
purified by the MinElute Kit (Qiagen), and pooled in equimolar
concentrations. Quality control of the libraries and sequencing on
a Roche 454 GS FLX1 platform (Roche, Basel, Switzerland) was
then carried out at IMGM Laboratories GmbH, Martinsried,
Germany.
We obtained a total of 183,291 TCRa reads and 182,245
TCRb reads, which were analyzed using the IMGT/HighV
QUEST platform.22 We selected for in-frame sequences that con-
tained the complete CDR3 region with clearly distinguishable
V and J genes only. Thereby we obtained 46,682 and 46,133
readable TCRa and TCRb chains, respectively.
RESULTS Vb11 T cells accumulate in inflammatory
foci and pair with MAIT cell–related a chains. It was
known that in patient A a particular T-cell clone express-
ing the Vb1-Jb2.3 TCRb chain was expanded in brain
lesions and persisted in peripheral blood and CSF
between 1996 and 2003.5,6 Immunohistochemistry
revealed clusters of Vb11CD81 cells within the CNS
(figure 1A). In some of these clusters, up to 38% of all
CD81 T cells coexpressed the Vb1 chain together with
CD8a. This observation links the clonal T-cell
expansions initially detected by CDR3 spectratyping
to morphologically identifiable accumulations of T cells.
To identify the TCRa chain associated with the
expanded Vb1-Jb2.3 chain, we double stained brain
sections of the 1996 tissue for CD8a and Vb1 and
isolated single CD8a1Vb11 T cells by laser micro-
dissection from brain sections (figure e-2A). In parallel,
we isolated single peripheral blood CD8a1Vb11 T
cells obtained in 2003 by flow cytometry (figure e-
2B). To distinguish probable antigen-experienced
Vb1-Jb2.31 T cells from bystanders, we tested all
Vb11 cells for their n(D)n-J sequences. For cells that
expressed the expanded and persisting sequence Vb1-
IGRKD-Jb2.3 (figure 1B), we analyzed the matching
a chain by multiplex PCR.11 We identified 15 a
chains that paired with the Vb1-Jb2.3 chain. One
T-cell clone was found 7 times in brain, and another
clone was found 6 times in blood (figure 1B). All a
chains share the Va7.2 element, and even though
they do not share the same Ja element, they all show
homologous CDR3a regions with the consensus
sequence valine, arginine (one clone: glutamine), as-
partic or glutamic acid, and a medium size hydro-
philic amino acid. Of note, 5 of 6 CDR loops of
the 4 ab heterodimers are identical because all clones
Figure 1 Expanded Vb1 chain pairs with MAIT cell–related a chains
(A) Cluster of expanded Vb11 T cells within multiple sclerosis (MS) lesions. Immunohisto-
chemistry for the expanded and persisting Vb1 clone (green) in clusters of CD81 T cells (red)
in parenchymal MS lesions. Several such clusters were observed. Only very few scattered
CD82Vb11 T cells could be identified in the brain lesion. Nuclei are visualized with 4’,6-
diamidino-2-phenylindole (white). Scale bar 20 mm. (B) Sequences of paired T-cell receptor
(TCR) a and b chains. Single sorted or laser microdissected Vb11CD81 T cells from periph-
eral blood or brain sections were submitted to single-cell TCR PCR to identify Vb1 chains and
all possible matching a chains. The V, n(D)n, and J regions are indicated. Amino acids encoded
by n(D)n nucleotides are printed in red. The expanded Vb1-Jb2.3 b chain (upper line) was
found to pair with 4 different a chains. Three a chains were identified from brain lesions, and
1 a chain was found in blood. The a chains expressing the Ja33 (second line) and Ja16 (fifth
line) elements were identified in 7 and 6 independent cells, respectively. All a chains share
the Va7.2 element, and even though they do not share the same Ja element, they all show
homologous complementarity determining region 3a regions with a conserved valine (V)
followed by a positively charged arginine (R) (with only one clone showing a glutamine [Q]),
a negatively charged amino acid (D/E), and a relatively large hydrophilic amino acid. One of
the a chains (highlighted in red) is the mucosal-associated invariant T (MAIT) cell canonical
TCR Va7.2-CAXXDSNYQLIW-Ja33 chain with 2 N nucleotide–encoded amino acids
between Va7.2 and Ja33 (here VR). The other clones with Ja16, Ja24.1, and Ja58 chains
are atypical for MAIT cells, which usually carry Ja33, Ja20, or Ja12. PBMC 5 peripheral
blood mononuclear cell.
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share the identical b chain and the Va7.2 variable
element. The common motif in the CDR3 loop of
the a chains therefore hints at related antigens. Strik-
ingly, one of the a chains identified from microdis-
sected brain-infiltrating CD81 T cells represents a
canonical MAIT cell a chain that contains 2 N amino
acids (X) in the CDR3a loop (CAXXDSNYQLIW)
and the Ja33 element.12,15 Thus, the expanded, dom-
inant, and persisting Vb1 chain found in earlier stud-
ies5,6 pairs with several distinct yet related Va7.21 a
chains.
Tissue-invading cells in early active lesions mostly show a
CD81 memory phenotype. The immune cell infiltrates
in lesions were dominated by CD81 T cells. Four
hundred twenty of 503 (84%) examined tissue-
infiltrating parenchymal CD31 T cells expressed
CD8a (figure 2A). The parenchymal CD4:CD8
ratio was 1:8 (figure 2B). Expression of the naive
T-cell marker CD45RA was found on only 11% of
tissue-infiltrating CD8a1 cells (figure 2C),
whereas 84% expressed the memory marker
CD45RO (figure 2D). Of all parenchymal
CD8a1 cells, 60% coexpressed the homing
receptor CCR7. Double staining of CCR7
together with CD45RA or CD45RO revealed the
following phenotypes in decreasing frequency:
central memory (CD45RO1CCR71), effector
memory (CD45RO1CCR72), and naive T cells
(CD45RA1CCR71), which accounted for only
6% of all CCR71 cells (figure 2E). Sixty-five
percent of CCR71 cells coexpress CD45RO, and
62% of all CD45RO1 cells express CCR7 (figure 2F).
Thus, the brain-infiltrating T cells predominantly
show a CD8a1CD45RO1CCR71 central memory
or CD8a1CD45RO1CCR72 effector memory
phenotype.
MAIT cells are detected in parenchymal MS lesions. To
investigate phenotypic features of the MAIT-related
cells, we stained brain sections for the expanded
Vb11 TCRb chain and MAIT cell–associated
markers Va7.2, CD161, and CD8a. Forty-two
percent of the parenchymal Va7.21 cells
coexpressed Vb1; however, only 13% of Vb11 T
cells expressed Va7.2 (figure 3A). Seventy percent
of the Va7.21 cells also expressed CD8a (figure
3B), and 69% of Va7.21 cells coexpressed CD161
(figure 3C), identifying them as MAIT cells.13 Of all
CD1611Va7.21MAIT cells, 74% were found in the
brain parenchyma. Comparing the number of
parenchymal CD1611Va7.21 cells to the total
number of parenchymal CD8a1 cells in consecutive
sections, we found that only about 1% of all CD8a1
cells belong to the CD1611Va7.21MAIT cell subset.
However, CD161 was found on 21% of CD8a1 T
cells. Conversely, about 80% of the CD161-expressing
cells were CD8a1 (figure 3D). Furthermore, about
80% of Vb11 T cells expressed CD1611 (data not
shown). This underlines the fact that many of the
CD1611 cells are not MAIT cells.23
Changes in the MAIT cell–related TCRa and TCRb
chain repertoire in blood between 1996 and 2014. To
follow the longitudinal development of the peripheral
T-cell repertoire from 1996 to 2014 (figure e-2), we
analyzed the 1996 brain sample as well as different
subsets of peripheral T cells from 2013 to 2014 by
pyrosequencing.
Tracking of TCR chains identified by single-cell
PCR in the 1996 biopsy specimen revealed that the
Vb1-Jb2.3 chain that was expanded in brain and
blood samples from 1996, 2001, and 20035,6 was still
detectable by pyrosequencing in peripheral T cells 18
Figure 2 Brain-infiltrating immune cells mainly consist of CD81 memory T cells
Immunofluorescence staining of brain-infiltrating immune cells. All nuclei are stained with
49,6-diamidino-2-phenylindole (white). Green and red dyes were used. Double-positive cells
are therefore shown in yellow. Scale bars 50 mm. (A) Double staining for CD3 (green) and
CD8a (red). Most CD31 T cells coexpress CD8a. (B) CD81 (red) T cells outnumber CD41
(green) T cells. (C) Low numbers of CD45RA1 (green) CD81 (red) double-positive T cells in
multiple sclerosis (MS) brain tissue. (D) Many CD81 T cells (red) coexpress CD45RO (green).
(E) Naive T cells double-positive for CCR7 (red) and CD45RA (green) are mostly found within
blood vessels and are barely detectable in the parenchyma of MS CNS. (F) Effector memory
(CD45RO1CCR72) (green arrow) and central memory (CD45RO1CCR1) (yellow arrow) T cells
in MS lesions.
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years after clinical onset, but it was no longer
expanded. Furthermore, the canonical Va7.2-
CAVRDSNYQLIW-Ja33 MAIT cell clone found
in the 1996 brain sample by single-cell PCR was still
present in the 2014 CD1611Va7.21 MAIT PBMC
subset, as found by pyrosequencing.
Next, we compared the CDR3 repertoires of
Va7.21 chains. We show the distribution of the
N and J regions of the 1996 brain specimen in figure
4A. One of the 3 dominant clones is a canonical MAIT
cell Va7.2-Ja33 clone, although it differs from the
clone found in the single cells. In peripheral blood
from 2014, clonal expansions were found in only the
CD1611Va7.21 subset, with the MAIT cell canonical
and noncanonical clones dominating (blue in figure
4B). In contrast, the CD1612Va7.21 subset is poly-
clonal (figure 4C). We also detected clonal expansions
including some typical sequences for MAIT cells in the
entire pool of CD81 T cells (figure 4D), whereas
CD41 T cells were polyclonal (figure 4E).
We then set out to identify distinct clones shared
between these different subsets (figure 4F). Within
the TCR Va7.2 repertoire, several clones that were
present in the 1996 brain sample can still be found in
blood T cells obtained 18 years after onset, especially
in the CD1611Va7.21MAIT cell subset. The great-
est overlap was observed between the CNS sample
and the PBMC MAIT cell sample from 2014, in
which 2.4% of all sequences were identical at the
amino acid level. It is notable that the canonical
Va7.2-CAVRDSNYQLIW-Ja33 sequence could
also be detected in T-cell subsets other than the
MAIT cells.
DISCUSSION For this in-depth analysis of CD81 T
cells in MS, we had the unique opportunity to
investigate a patient whose initial inflammatory
lesion was resected under the misdiagnosis of
glioma5 and whom we have been following for 18
years. By combining immunohistochemistry, laser
microdissection, and single cell PCR analysis of
brain-infiltrating Vb11Jb2.31 cells, we show that
the expanded and persistent Vb1-Jb2.31 T-cell
population6 comprises several distinct Va7.21 T-
cell clones, all of which bear striking similarities in
their CDR3a regions. In addition to a canonical
MAIT cell Va7.2-Ja33 chain, we identified 3
MAIT cell–atypical Va7.2 chains with different yet
related CDR3a regions that form an oligoclonal
spectrum of heterodimeric ab TCRs.
Figure 3 MAIT cells can be detected within parenchymal lesions of MS brain
Double fluorescence immunohistochemistry identifies brain-infiltrating mucosal-associated invariant T (MAIT) cells in mul-
tiple sclerosis (MS) lesions of patient A. Nuclei are stained with 4’,6-diamidino-2-phenylindole (white). Green and red dyes
were used. Double-positive cells are therefore shown in yellow. Scale bars 20 mm. (A) T cells expressing the T-cell receptor
Va7.2 (red) and Vb1 chains (green). This combination (see figure 1B) was identified by single-cell PCR. (B) Most Va7.21
(green) T cells belong to the CD81 (red) T-cell subset. (C) MAIT cells expressing Va7.2 (red) and CD161 (green) in the
parenchyma of MS brain. (D) The vast majority of CD1611 (green) cells in MS CNS coexpress CD8a (red).
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Transcripts of canonical Va7.2-Ja33 MAIT cells
have been identified in MS brain autopsies,24 but it
remained unclear whether the MAIT cells indeed in-
filtrated the parenchyma. Later, phenotypically defined
(CD31CD1611Va7.21 or CD81CD1611Va7.21)
bona fide MAIT cells were detected in brain and
meningeal infiltrates, mostly of patients with long-
standing progressive disease.25–28 Consistent with these
studies, we found that CD1611Va7.21 MAIT cells
represented only about 1% of CD81 T cells present in
the brain specimen of our patient. This is lower than
the typical MAIT cell frequency of 3%–10% of all
T cells in blood,13,29 suggesting that MAIT cells are
not selectively recruited into the CNS. CD161
expression is not limited to MAIT cells,23 and we
found CD161 expression on 21% of all CD81 T cells
in our patient’s brain lesions. Furthermore, we found
more CD1611Vb11 cells than Va7.21Vb11 T cells,
indicating that most brain-infiltrating CD1611Vb11
cells do not belong to the CD1611Va7.21MAIT cell
subset. However, despite their low numbers, the brain-
infiltrating Vb11Va7.21 cells are unlikely to represent
a randomly recruited bystander population. First, their
clonal features strongly point to an antigen-driven pro-
cess: a single strikingly expanded TCR Vb1 chain was
found to be associated with 4 different Va7.2 chains
that all shared highly homologous CDR3 regions. Sec-
ond, the expanded Vb11 T cells formed conspicuous
Figure 4 Va7.2 TCR chain repertoire
Analysis of the T-cell receptor (TCR) Va7.2 repertoire of patient A by pyrosequencing shows oligoclonal T-cell expansions in different samples. Each pie
chart represents the total number of nucleotide sequences found in the Va7.2 repertoire of a certain compartment and each sector represents one distinct
T-cell clone. We compared (A) samples from CNS tissue from the biopsy taken in 1996, (B) Va7.21CD1611 mucosal-associated invariant T (MAIT) cells, (C)
Va7.21CD1612 cells, (D) CD81 cells, and (E) CD41 T cells from peripheral blood taken in 2013 and 2014. For each population we list the designation of the
Ja elements and their relative percentage. Clones carrying the MAIT canonical TCR a chain (CAXXDSNYQLIW) are marked in bright blue, and clones
containing the noncanonical a chains characterized by Ja12 (CAXXDSSYKLIF) and Ja20 (CAVXXDYKLSF) are marked in dark blue and light blue, respec-
tively. (F) Percentages of identical complementarity determining region 3a amino acid sequences within the TCR Va7.21 repertoire between the different
samples defined above (A–E). The numbers are percentages indicating how often a particular sequence detected in one sample was also found in another
sample. The greatest overlap was between Va7.21CD1611 and CD81 T cells from peripheral blood, but there was also significant overlap between the CNS
sample and the Va7.21CD1611 sample from 2013 to 2014, as highlighted by the red and yellow colors. PBMC 5 peripheral blood mononuclear cell.
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local clusters, consistent with local recognition of
shared antigen(s). Third, the brain specimen was ob-
tained at clinical disease onset and contains early active
lesions, pointing to an early role of these inflammatory
cells. Fourth, Vb1-Jb2.31 clones were still expanded
in CSF and/or blood 7 years after disease onset.6
Because the MAIT TCR repertoire depends on
the commensal gut microbiota17 and may be shaped
by microbes,19 the presence of MAIT cells in MS
brain would be consistent with the hypothesis of a
“gut–brain axis.”30 Recent evidence indicates that
some MAIT cells recognize bacterial vitamin B me-
tabolites presented by MR1,15,16,31,32 but these clones
express canonical N-Ja elements and b chains that are
very different from our Vb1 chain. However, our
brain-derived T-cell clones do not react with these
metabolites nor do they recognize Escherichia coli–
infected HeLa cells in a standard MAIT assay
(unpublished observations). Another possibility is
that these cells recognize conventional peptide anti-
gens, but our efforts to identify such peptides have
not been successful. A third possibility is that they
might recognize other, still-unknown low-molecular-
weight ligands. A recent study19 showed that exposure
to different microbes evoked expression of atypical Ja
and Vb elements of MAIT cells. This would be con-
sistent with our observation that except for one clone
with a canonical Ja331 a-chain, our clones express a
chains with varying CDR3a lengths and Jb elements
that are atypical for MAIT cells. Furthermore, the
Ja16, Ja24.1, and Ja58 chains lack the conserved
Tyr 95a required for MAIT cell antigen recogni-
tion,15 and all 4 of our brain-derived T clones express
Vb1, which is very atypical for MAIT cells.
Our results reveal several novel features of CD81
T cells in MS. First, the complexity of the ab TCR
repertoire is far greater than could be assumed from
the TCRb chain repertoire alone. Second, the ab
TCR dimers we obtained from individual brain-
invading CD81 T cells show MAIT-related features.
Third, the brain-infiltrating MAIT-related cells
themselves are heterogeneous; they express either a
public “canonical” Va7.2 chain or private MAIT-
atypical Va7.2 chains. Fourth, although histochemi-
cal stainings indicate that the MAIT-related T cells
constitute only a small fraction of the infiltrate, the
striking homology of the TCR CDR3 regions of the
identified panel of Va7.2-Vb11 T-cell clones points
to their antigen-driven recruitment into early MS
lesions. Fifth, follow-up of the peripheral TCR rep-
ertoire of the index patient by next-generation
sequencing reveals that some MAIT-related TCR se-
quences are still detectable in blood 18 years after
clinical onset. Sixth, the observation that a small yet
clonally conspicuous fraction of CD81 T cells in early
MS lesions consist of MAIT or MAIT-related cells
provides a hypothetical link between the brain-
infiltrating T cells and the gut microbiota. Currently,
the precise functional role of the brain-infiltrating
MAIT cells is unknown: they could be harmful, pro-
tective, or inert. Future studies will attempt to tackle
the complex interplay between the different CNS-
invading T cells and their target tissue.
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